ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/29/2025
Back to search
Official data from USPTO
BEIGENE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
10/30/2025
Trademark type
Combined
Nice classes
5, 40, 42, 44
Filing date
04/15/2021
Registration date
09/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2022
Last transaction
10/30/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/20/2021
First use in commerce
09/20/2021
Drawing code
3
Owner type
16
Owner location
BASEL, CH
Examiner
KETCHUM,BRENDAN J
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a shaded square in red with a stylized red square and a star cutout in the center of the stylized square to the left of the black wording "BeiGene" with a red arrow as part of the letter "G.
Holders and representatives
Holders
BEONE MEDICINES I GMBH
BG NC 1, LTD.
BEONE MEDICINES LTD.
BeiGene, Ltd.
BeiGene, Ltd.
Representatives
Kristen S. Ruisi VENABLE LLP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases
Class 40
Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases
Class 42
Research and development of new products for others; technological research in the field of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancerautoimmune and inflammatory diseasesrheumatoid arthritiscardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database managementword processingspreadsheet managementtracking; packaging design
Class 44
Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advicepharmaceutical advice
Publications
History of USPTO decisions and trademark events.
42 publications found
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/10/2025
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/09/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/24/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/24/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/24/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/08/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/08/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/08/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/08/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/08/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/27/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/23/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/22/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/19/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/18/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/18/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/11/2022
GNFR
FINAL REFUSAL E-MAILED
08/11/2022
CNFR
SU - FINAL REFUSAL - WRITTEN
08/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/07/2022
GNRT
NON-FINAL ACTION E-MAILED
07/07/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
07/07/2022
DMCC
DATA MODIFICATION COMPLETED
06/01/2022
ALIE
ASSIGNED TO LIE
06/01/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/26/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/26/2022
IUAF
USE AMENDMENT FILED
05/12/2022
EISU
TEAS STATEMENT OF USE RECEIVED
05/12/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/14/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/19/2021
PUBO
PUBLISHED FOR OPPOSITION
10/19/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/29/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/13/2021
DOCK
ASSIGNED TO EXAMINER
09/08/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/23/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/22/2021
NWAP
NEW APPLICATION ENTERED
04/19/2021
Continuous trademark protection
Get notified about every new filing that threatens BEIGENE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.